Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer

• Hauptverfasser: Jaime D. Lewis (VerfasserIn), Anees B. Chagpar (VerfasserIn), Elizabeth A. Shaughnessy (VerfasserIn), Jacob Nurko (VerfasserIn), Kelly McMasters (VerfasserIn), Michael J. Edwards (VerfasserIn)
• Format: Buch
• Veröffentlicht: ABV-press, 2014-11-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer would result in equivalent surv...